Low Unit of Measure (LUM) UDI
Single Device Work Group Report
Supply Chain Best Practices: LUM and UDI Implementation
PURPOSE:
The goal of this document is to provide a guide for supply chain partners to begin a dialogue to ensure that medical devices comply with FDA’s Unique Device Identification (UDI) requirements as well as meet the FDA’s goal of enhancing patient safety. Low Unit of Measure (LUM) programs are complex and the steps outlined in this best practices document are a critical first step. We expect this to be an ongoing process as additional opportunities for stakeholder collaboration continue to arise.

On September 24, 2013, the FDA issued the final Unique Device Identifier (UDI) rule intended to adequately identify medical devices through their distribution and use. UDI includes a series of numeric or alphanumeric characters that have been assigned to a product as a Device Identifier (DI). UDI also may include one or more Production Identifier(s) (PI) (lot, expiry, etc.) along with the DI on the medical device packaging label and on the device itself in both a machine readable and human readable format. There are also requirements on submitting essential product data into the Global Unique Device Identification Database (GUDID) database and to use UDI across the device lifecycle. (Please refer to the FDA UDI regulation for complete details.)

The UDI Rule applies broadly to all medical devices. However, because of the diversity and complexity of medical devices, FDA has offered limited alternatives, extensions, and exceptions to the UDI regulatory requirements. The FDA Single-Use Device Exception\(^1\) coupled with an evolving Low Unit of Measure (LUM) market created the need for further examination of UDI practices in the healthcare supply chain around this device distribution model. At the request of HIDA and several distributors, FDA granted a two-year extension for medical device distributors and manufacturers to revisit their respective UDI implementation efforts and to further collaborate to ensure that the UDI requirements are still being met after products have been removed from the device package that contains multiple devices of the same model/version by the distributor for LUM distribution.

BACKGROUND:

Low Unit of Measure/Just in Time Programs (LUM/JIT):
LUM and JIT programs are used by medical device distributors to better support healthcare provider needs for improved efficiencies and better patient care by:

- Allowing products to go directly to patient care areas
- Optimizing provider inventory levels to improve cash flow
- Maximizing provider focus on the delivery of care
- Reducing total costs of doing business as well as see a reduction of material and waste

---

\(^1\) Single-Use Device General Exception § 801.30 (a)(3)
Individual single-use devices, all of a single version or model, that are distributed together in a single device package, intended to be stored in that device package until removed for use, and which are not intended for individual commercial distribution. This exception is not available for any implantable device. The device package containing these individual devices is not excepted from the requirement of § 801.20, and must bear a UDI.
LUM Challenge Related to UDI: The FDA UDI regulation requires that devices be adequately identified through distribution and use. LUM programs may result in the device being removed from the UDI compliant packaging by the distributor in order to provide individual products to healthcare providers to enhance patient care. Once the device is removed from the package, it may no longer meet UDI compliant packaging standards if the device is not originally labeled at the “each” level. Manufacturers and distributors need to collaborate to ensure that FDA’s UDI requirements are being met for the products that are distributed via LUM programs.

RECOMMENDED LUM/SINGLE-USE DEVICE UDI ASSURANCE PROCESS:

Communication is essential for distributors and manufacturers to develop meaningful plans to comply with UDI regulations. Accurate data and a clear understanding of distributor LUM programs are essential inputs for a successful UDI implementation. Device manufacturers need an understanding of distributor programs and needs in order to further implement UDI in a way that safely supports LUM programs. The process below can assist in creating a clear mutual understanding to ensure UDI compliance in the healthcare supply chain.

STEP #1: Initiate Trading Partner Discussion
The distributor and manufacturer need to mutually understand the distributor’s LUM programs and develop a plan to comply with UDI. Anti-trust considerations necessitate that these conversations be conducted one-on-one between individual trading partners.

STEP #2: Share Key Data
Distributor to share a list of products distributed in LUM/JIT programs. Data needs may vary by trading partner relationship.

STEP #3: Analysis
Manufacturer to review distributor data. Manufacturer to gather up-to-date UDI implementation plans from their product teams based on the distributor’s data. The device manufacturer to determine if/when gaps exist as a result of LUM distribution. The device manufacturer should also assess the suitability of products in a LUM program.

STEP #4: Dialogue
Manufacturer to provide distributor with a response of how they are preparing for UDI for products sold via LUM programs. The device manufacturer should provide a summary of the status of the product line in advance of the applicable FDA UDI product compliance date. Discussions may necessitate:

- **Deeper data dive:** Initial discussion may highlight the need for additional information to determine the best UDI solution.

- **Provider input:** Frequency of their usage in LUM programs and may trigger the need for discussions with healthcare providers to understand more about the impact on patient care. Additionally, healthcare provider input and reimbursement requirements may indicate why products are being distributed via LUM programs.

STEP #5: Develop a Plan
Manufacturer and distributor to decide on how to proceed with UDI implementation and determine how to communicate to their provider customers.
STEP #6: Continued Dialogue
Plans change. Markets evolve. Distributors and manufacturers should maintain continued dialogue and ensure that the FDA UDI requirements are being met and that all applicable label regulations are being maintained.

POSSIBLE SOLUTIONS TO ENSURE UDI COMPLIANCE:
The AHRMM LUC UDI Work Group identified three possible scenarios for managing products that have been removed from their UDI compliant packaging by a distributor for a LUM program. The three scenarios are:

1. **IDEAL CANDIDATE FOR LUM**
   - High value to patient
   - High value to provider
   - High value to supply chain efficiency
   - High frequency of use

2. **NOT IDEAL CANDIDATE FOR LUM**
   - Low value to patient
   - Low value to provider
   - Low value to supply chain efficiency
   - Low frequency of use
   - Other special requirements impede use for LUM

3. **REQUIRES ALTERNATIVE PACKAGING SOLUTION**
   - Special handling needed
   - Reimbursement requirements
   - Size of package too small
   - Or other unique circumstances

SUMMARY:
LUM is a growing market trend that healthcare providers value. The FDA UDI regulation is here to stay and device manufacturers and distributors must ensure that all applicable regulations are being adhered to. Communication and the sharing of information between trading partners are essential. At the end of these discussions, distributor, and device manufacturers should develop a plan that specifies what each organization is responsible for. Medical device distributors and manufacturers have traditionally collaborated to meet market needs and we expect that the same spirit will carry over into the LUM challenge that we are currently facing.

Legal Disclaimer: The contents of this best practices document are not intended as legal advice nor as legally binding, and should not be construed or acted upon as such.
APPENDIX

<table>
<thead>
<tr>
<th>Type of Device</th>
<th>Label (21 CFR 801.20), GUDID Submission (21 CFR Part 830, subpart E), and Standard Date Format (21 CFR 801.18) Requirements</th>
<th>Direct Mark (21 CFR 801.45) Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I devices***</td>
<td>September 24, 2018</td>
<td>September 24, 2022</td>
</tr>
<tr>
<td>Certain class II devices**</td>
<td>September 24, 2018</td>
<td>September 24, 2022</td>
</tr>
<tr>
<td>Unclassified devices</td>
<td>September 24, 2020</td>
<td>September 24, 2022</td>
</tr>
</tbody>
</table>

For implantable, life-supporting or life-sustaining devices of all classes, the compliance date for all UDI requirements and the standard date format requirement (21 CFR 801.18) was September 24, 2015.

**The FDA extended this deadline from September 24, 2016 to September 24, 2018. This is not a blanket extension for all class II devices. Instead, it refers to device constituent parts of certain combination products, repackaged class II single-use devices that are not individually labeled with a UDI (i.e. single-use devices broken down to the each for low unit of measure), and collections of two or more different class II, or class II and class I, devices packaged together in which the devices in the package are not individually labeled with a UDI.


GENERAL EXCEPTIONS:
Under § 801.30, the UDI rule provides general exceptions from UDI labeling requirements to certain categories of devices. A device within one or more of these exceptions is not required to bear a UDI. A labeler of a device identified in § 801.30 is not required to request an exception from FDA. The final rule:

<table>
<thead>
<tr>
<th>§801.30(a)1</th>
<th>Provides an exception for a finished device that is manufactured and labeled prior to the compliance date that applies to that device (exception expires 3 years after the compliance date)</th>
</tr>
</thead>
<tbody>
<tr>
<td>§801.30(a)(2) *see table on page 6</td>
<td>Provides an exception for a class I device that FDA has by regulation been exempted from the good manufacturing practice (GMP) requirements*</td>
</tr>
<tr>
<td>§801.30(a)(3)</td>
<td>Provides an exception for certain individual single-use devices (SUDs), regardless of class, except that this exception is not available for any implantable device - the device package containing these individual devices must bear a UDI</td>
</tr>
<tr>
<td>§801.30(a)(11)</td>
<td>Expects the device constituent part packaged within a combination product from the requirement that its label bear a UDI, if the combination product bears a UDI</td>
</tr>
<tr>
<td>§801.30(a)(11)</td>
<td>Does not require devices contained within a convenience kit to bear a UDI but does require the label and each device package of every convenience kit to bear a UDI</td>
</tr>
<tr>
<td>§801.40(d)</td>
<td>Provides that a class I device labeled with a Universal Product Code (UPC) may use the UPC as its UDI</td>
</tr>
<tr>
<td>Product Code</td>
<td>Examples of Class I Devices Exempted from GMP Requirements</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>FOB</td>
<td>Bedpan</td>
</tr>
<tr>
<td>ILI</td>
<td>Arm Sling</td>
</tr>
<tr>
<td>IPR</td>
<td>Crutch</td>
</tr>
<tr>
<td>ITJ</td>
<td>Mechanical Walker</td>
</tr>
<tr>
<td>KIZ</td>
<td>Tissue Culture Dish</td>
</tr>
</tbody>
</table>


**USEFUL LINKS:**

- **Product Classification Database:** [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm)
- **FDA Letter to Device Labelers (September 6, 2016):** [https://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UCM519346.pdf](https://www.fda.gov/downloads/MedicalDevices/ResourcesforYou/Industry/UCM519346.pdf)
- **FDA UDI Help Desk:** [https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/UniqueDeviceIdentification/ucm368904.htm](https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/UniqueDeviceIdentification/ucm368904.htm)
- **Compliance Dates for UDI Requirements:** [https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/UniqueDeviceIdentification/ComplianceDatesforUDIRequirements/default.htm](https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/UniqueDeviceIdentification/ComplianceDatesforUDIRequirements/default.htm)

**THANK YOU TO THE FOLLOWING WORK GROUP MEMBERS:**

- Alex Caldwell, Claflin
- Bill Crates, Cardinal Health
- Billy Almon, Claflin
- Bryan Fagnani, Lynn Medical
- Carl Kennedy, ThermoFisher
- Carlos Chaparro, Bovie
- Jodi King, Philips
- Kathleen Devaney, Henry Schein
- Kevin Neuman, Innovative Healthcare Corporation
- Kyle Gurney, VCU Health
- Lena Cordie, Qualitas Professional Services, LLC.
- Linda Rouse O’Neill, HIDA
Carol Baum, Medline
Claire Mansbach, HIDA
Curt Wilens, Cardinal Health
Dennis Black, BD
Doug Caro, McKesson
Elizabeth Valentine, Owens & Minor
Ellenmary Martin, Dukal
Erin Salbilla, Vyaire
Frank Pokrop, CareFusion
Gary Tiamsic, Henry Schein
Greg Laird, NDC
Indira Konduri, FDA
Jay Crowley, USDM Life Sciences
Jeff Peacock, Henry Schein
Jim Booker, Stanford Health Care
Loretta Chi, FDA/CDRH/OSB/Informatics
Mary Gray, Johnson & Johnson
Matt Shiraki, McKesson
Michael Oliver, Claflin
Mike Marchlik, Owens & Minor
Mike Nolan, AIS
Peter Sadler, Henry Schein
Rich Paul, Henry Schein
Ryan McBee, DeRoyal
Sergio Tejeda, Henry Schein
Shari Bouche, Cardinal Health
Tim Fenton, ThermoFisher
Tim Sleddens, Cerner Corporation
Zita Yurkom, Philips
Blair Korman, Johnson & Johnson